Lumos Pharma LUMO Stock
2.64 USD
{{ price }}
-7.042247%
{{change_pct}}%
SECTOR
Healthcare
INDUSTRY
Biotechnology
COUNTRY
United States
Exchange
NasdaqGM
Market Cap
21.4M USD
LOW - HIGH [24H]
2.41
-
2.72 USD
VOLUME [24H]
15.34K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-4.18 USD
Lumos Pharma Price Chart
Lumos Pharma LUMO Financial and Trading Overview
| Lumos Pharma stock price | 2.64 USD |
| Previous Close | 3.62 USD |
| Open | 3.54 USD |
| Bid | 0 USD x 1300 |
| Ask | 0 USD x 1300 |
| Day's Range | 3.53 - 3.75 USD |
| 52 Week Range | 2.95 - 9.56 USD |
| Volume | 10.01K USD |
| Avg. Volume | 16.17K USD |
| Market Cap | 30.23M USD |
| Beta (5Y Monthly) | 0.631002 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.18 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.33 USD |
LUMO Valuation Measures
| Enterprise Value | -27984696 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.1349694 |
| PEG Ratio (5 yr expected) | -0.06 |
| Price/Sales (ttm) | 14.37516 |
| Price/Book (mrq) | 0.5765036 |
| Enterprise Value/Revenue | -13.307 |
| Enterprise Value/EBITDA | 0.866 |
Trading Information
Lumos Pharma Stock Price History
| Beta (5Y Monthly) | 0.631002 |
| 52-Week Change | -44.61% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 9.56 USD |
| 52 Week Low | 2.95 USD |
| 50-Day Moving Average | 3.46 USD |
| 200-Day Moving Average | 5.04 USD |
LUMO Share Statistics
| Avg. Volume (3 month) | 16.17K USD |
| Avg. Daily Volume (10-Days) | 15.93K USD |
| Shares Outstanding | 8.17M |
| Float | 4.82M |
| Short Ratio | 6.25 |
| % Held by Insiders | 38.43% |
| % Held by Institutions | 30.03% |
| Shares Short | 173.77K |
| Short % of Float | 3.00% |
| Short % of Shares Outstanding | 2.13% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1537.99% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -25.76% |
| Return on Equity (ttm) | -45.68% |
Income Statement
| Revenue (ttm) | 2.1M USD |
| Revenue Per Share (ttm) | 0.25 USD |
| Quarterly Revenue Growth (yoy) | 522.50% |
| Gross Profit (ttm) | 1.52M USD |
| EBITDA | -32298000 USD |
| Net Income Avi to Common (ttm) | -30688000 USD |
| Diluted EPS (ttm) | -3.64 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 57.98M USD |
| Total Cash Per Share (mrq) | 7.1 USD |
| Total Debt (mrq) | 421K USD |
| Total Debt/Equity (mrq) | 0.8 USD |
| Current Ratio (mrq) | 12.608 |
| Book Value Per Share (mrq) | 6.418 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -27787000 USD |
| Levered Free Cash Flow (ttm) | -17344000 USD |
Profile of Lumos Pharma
| Country | United States |
| State | TX |
| City | Austin |
| Address | 4200 Marathon Boulevard |
| ZIP | 78756 |
| Phone | 512 215 2630 |
| Website | https://lumos-pharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 33 |
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its primary product candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 3 clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Q&A For Lumos Pharma Stock
What is a current LUMO stock price?
Lumos Pharma LUMO stock price today per share is 2.64 USD.
How to purchase Lumos Pharma stock?
You can buy LUMO shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Lumos Pharma?
The stock symbol or ticker of Lumos Pharma is LUMO.
Which industry does the Lumos Pharma company belong to?
The Lumos Pharma industry is Biotechnology.
How many shares does Lumos Pharma have in circulation?
The max supply of Lumos Pharma shares is 8.11M.
What is Lumos Pharma Price to Earnings Ratio (PE Ratio)?
Lumos Pharma PE Ratio is now.
What was Lumos Pharma earnings per share over the trailing 12 months (TTM)?
Lumos Pharma EPS is -4.18 USD over the trailing 12 months.
Which sector does the Lumos Pharma company belong to?
The Lumos Pharma sector is Healthcare.
Lumos Pharma LUMO included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}